Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.60 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.53 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17603205 | 0.88 | AR (0.63) | ARKCNQ3KCNQ2SCN10ABRAF | |
| SCHEMBL19776339 | 0.80 | KCNQ3 (0.56) | ARKCNQ3KCNQ2SCN10ABRAF | |
| SCHEMBL3305812 | 0.78 | AR (0.57) | ARKCNQ3KCNQ2SCN10ABRAF | |
| SCHEMBL1483167 | 0.77 | KCNQ3 (0.53) | ARKCNQ3KCNQ2SCN10ABRAF | |
| SCHEMBL31680457 | 0.76 | AR (0.59) | ARKCNQ3KCNQ2BRAFCHEK1 | |
| SCHEMBL20942380 | 0.76 | AR (0.59) | ARKCNQ3KCNQ2SCN10ABRAF | |
| SCHEMBL13036452 | 0.76 | AR (0.59) | ARKCNQ3KCNQ2BRAFCHEK1 | |
| SCHEMBL1483561 | 0.76 | MAPT (0.56) | ARKCNQ3KCNQ2CHEK1NPC1 | |
| SCHEMBL1483214 | 0.76 | KCNQ3 (0.52) | ARKCNQ3KCNQ2SCN10ABRAF | |
| SCHEMBL27857353 | 0.76 | KCNQ3 (0.52) | ARKCNQ3KCNQ2SCN10ABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314103-B2 | Pyridyl derivatives, their preparation and use | Piramal Enterprises Limited (IN) | 2012-11-20 | — | — | US | disclosed |
| US-20110077252-A1 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE | Piramal Enterprises Limited (IN) | 2011-03-31 | — | — | US | disclosed |
| WO-2009019656-A1 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077252-A1 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE | HIF1AN, HIF1A, MTOR | AR 3332/4885KCNQ3 4563/4885KCNQ2 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.